Skip to content

Arteris, Inc. AIP Accrued offering costs

Accrued offering costs at other companies

TRV
Trevi Therapeutics, Inc.TRVI
$58.25K
TRV
Trevi Therapeutics, Inc.TRVI
$58.25K
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$106K
Cal-Maine Foods logo
Cal-Maine FoodsCALM
$1.7M
NTS
Netskope, Inc. Class A Common StockNTSK
$0-100%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$136K

Other financials

Income statement

See full
Revenue$22.9M+38.7%
Gross profit$19.7M+31.2%
Operating income-$9.3M-20.7%
Net income-$8.0M+2.0%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$12.0M-28.3%
Total debt$5.5M+20.2%
Total equity$2.6M+154%
Total assets$139.9M+42.3%

Cash flow

See full
Operating cash flow-$7.1M-347%
CapEx$295.0K+61.2%
Free cash flow-$7.4M-375%

Valuation

See full
Market cap$1.9B+164%
Enterprise value$1.9B+174%
P/S24.7×+13.0×

Profitability

See full
Gross margin88.8%-1.4pp
Operating margin-45.1%-3.5pp
Net margin-44.9%-5.8pp
FCF margin-6.1%-8.3pp

Returns & leverage

See full
Return on equity-296.8%-687pp
Debt / equity2.1×
Current ratio0.7×-0.3×

Where this comes from

Reported directly by Arteris, Inc. in its filing.

Tagged under the XBRL concept aip:AccruedDeferredOfferingCosts.

The official record: Arteris, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arteris, Inc.'s accrued offering costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arteris, Inc.'s accrued offering costs?
Arteris, Inc. (AIP) reported accrued offering costs of $296K in Q1 2026.
What does accrued offering costs mean?
This represents costs incurred in connection with the issuance of equity or debt securities that have been deferred and are pending recognition or offset against proceeds. These costs typically include legal, accounting, and underwriting fees associated with capital raising activities. It provides insight into the capital structure management and the efficiency of the company's financing efforts.